Regeneron Pharmaceuticals, Inc. (REGN)
Why Is Regeneron (REGN) Down 4.1% Since Last Earnings Report?
Regeneron (REGN) reported earnings 30 days ago. What's next for the stock?
Regeneron Pharmaceuticals, Inc. (REGN) TD Cowen 45th Annual Health Care Conference (Transcript)
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) TD Cowen 45th Annual Health Care Conference March 4, 2025 11:50 AM ET Company Participants Marion McCourt - EVP, Commercial Ryan Crowe - SVP, IR Conference Call Participants Tyler Van Buren - TD Cowen Tyler Van Buren Good morning, everyone. Tyler Van Buren here, senior biotech analyst at TD Cowen.
Regeneron Gets Positive CHMP Opinion for Multiple Myeloma Drug
The CHMP recommends conditional marketing authorization of REGN's linvoseltamab to treat adults with relapsed and refractory multiple myeloma.
Regeneron's gene therapy study shows improved hearing in children with congenital deafness
Regeneron Pharmaceuticals said on Monday its experimental gene therapy showed improved hearing in 10 of 11 children between 10 months and 16 years old born with hearing loss caused by gene mutations.
This Company Just Initiated a Quarterly Dividend: Time to Buy?
Biotech giant Renegeron Pharmaceuticals (REGN -0.10%) reported its fourth-quarter and full-year 2024 earnings on Feb. 4. The company's results were strong, coming in ahead of analyst estimates.
Why Regeneron's Price May Soon Break Out
On February 4, Regeneron released financial results for the fourth quarter of 2024, which beat my and Wall Street analysts' expectations. The main contributors to its revenue and operating income growth were Dupixent and Libtayo, which were able to minimize the decline in demand for Eylea in the United States. In this article, dear Seeking Alpha readers, you will learn about 5 reasons why I believe REGN is an appealing stock for long-term investors.
Regeneron Is Playing Defense With Capital Allocation
Regeneron has started 2025 with an increase in defensive capital allocation - initiation of a dividend and an expanded share buyback program. Increased competitive pressure on the Eylea franchise is to be expected this year, from branded competition to biosimilar Eylea. Dupixent and Libtayo should be enough to offset Eylea franchise erosion and drive low to mid-single digit topline growth in 2025.
Regeneron Presents An Opportunity After LIBTAYO Sales Growth Bolsters Earnings
Regeneron reported Q4 earnings on Tuesday, with revenues up 10% versus Q4 in 2023. EYLEA HD has stabilized its franchise with a modest sales growth of 1% in 2024 versus 2023. Biosimilar competition has been a headwind, but signs point to stabilization. In a surprise announcement, Regeneron began a dividend at $0.88/share. A ~$4.5B share repurchase program adds further value.
Why Regeneron Pharmaceuticals Stock Topped the Market on Tuesday
News of a significant earnings beat propelled Regeneron Pharmaceuticals (REGN 4.53%) to a nearly 5% share price gain on the second trading day of the week. The company posted its fourth-quarter and full-year 2024 results before market open, and investors were clearly impressed by the numbers.
Regeneron Beats on Q4 Earnings, Initiates Quarterly Dividend
Regeneron Pharmaceuticals, Inc. REGN reported fourth-quarter 2024 earnings per share (EPS) of $12.07, which beat the Zacks Consensus Estimate of $11.62. The company recorded an EPS of $11.86 in the year-ago period.
Regeneron Q4 Earnings: Dividend And Dupixent Drive Solid Quarter - Eylea To Strike Back In 2025
Regeneron Q4 Earnings: Dividend And Dupixent Drive Solid Quarter - Eylea To Strike Back In 2025
Regeneron Pharma Q4 Earnings Crush Estimates, Initiates Dividend And Additional Stock Buyback Program
On Tuesday, Regeneron Pharmaceuticals Inc REGN reported fourth-quarter adjusted EPS of $12.07, up 2% year-over-year, beating the consensus of $11.29.
